NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol

  • Clinical Trial Information

    Trial Contact: Spinelli, Jennifer; Armatti, Julie M; Doyle, Katherine M; Parker, Melanie

  • IRB No: APEC1621

    Protocol Abbrev: APEC1621

    Principal Investigator:

    Phase: Drug: Phase II

    Age Group: Pediatric

    Secondary Protocol No: APEC1621

    Treatment: olaparib, vemurafenib, ensartinib, selumetinib sulfate, PI3K/mTOR Inhibitor LY3023414, Tazemetostat, Erdafitinib, Larotrectinib, palbociclib, Ulixertinib, Ivosidenib, Zamestra

    Therapies Involved: Chemotherapy ID: NCT03155620

  • Objective

    This screening and multi-sub-study phase II trial studies how well treatment that is directed by genetic testing works in pediatric patients with solid tumors, non-Hodgkin lymphomas, or histiocytic disorders that have progressed following at least one line of standard systemic therapy and/or for which no standard treatment exists that has been shown to prolong survival.

  • Key Eligibility

    Ages Eligible for Study: 12 Months to 21 Years (Child, Adult)
    Sexes Eligible for Study: All
    Accepts Healthy Volunteers: No